Table 1.
Comparison of the characteristics between never users and current users
| Never users, n (%) | Current users, n (%) |
p value (Chi2) |
|
|---|---|---|---|
| Total | 7295 (100) | 377 (100) | |
| Sex | <.05* | ||
| Boys | 3275 (44.9) | 298 (79.0) | |
| Girls | 4020 (55.1) | 79 (21.0) | |
| Ethnicity | <.05* | ||
| Dutch | 6407 (87.8) | 358 (95.0) | |
| non-Dutch | 888 (12.2) | 19 (5.0) | |
| Parent Household | .656 | ||
| Two-parent household | 5987 (82.1) | 306 (81.2) | |
| single-parent household | 1308 (17.9) | 71 (18.8) | |
| Household income | <.05* | ||
| low | 3010 (41.3) | 171 (45.4) | |
| intermediate | 3176 (43.5) | 166 (44.0) | |
| high | 1109 (15.2) | 40 (10.6) | |
| Treated concurrently with | |||
| Asthma medication | 100 (1.4) | 11 (2.5) | <.05* |
| Antipsychotics | 19 (4.3) | ||
| Only MPH users | 347 (78.7) | ||
| Start of MPH treatment | |||
| Late ≤12 months | 38 (10.1) | ||
| Early >12 months | 339 (89.9) | ||
| Dosage of MPH treatment | |||
| ≤ 0.999 NDDD/Day | 202 (53.6) | ||
| > 0.999 NDDD/Day | 132 (35.0) | ||
Abbreviations: n, sample size; NDDD, number of Defined Daily Dose
* Significant at .05 level